Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Ketorolac tromethamine dispersible tablets 10 mg price?Market share ingrezza vs austedo for td 2025?Idelvion side effects?Spiriva inhalation spray?Ingrezza vs austedo market share tardive dyskinesia 2025?
See the DrugPatentWatch profile for isotretinoin
Current Spain Isotretinoin Market Dynamics The Spain isotretinoin market, which includes drugs used to treat severe acne, is a significant segment of the country's pharmaceutical industry. Market Size and Growth According to the latest data from DrugPatentWatch.com, the Spain isotretinoin market size is approximately €30 million (2023 estimates). This number is expected to grow due to the increasing demand for acne treatments and the entry of new generic options. Key Players The major players in the Spain isotretinoin market include pharmaceutical companies such as Roche and Pfizer. Roche's Accutane (isotretinoin capsules) is the leading brand in the Spain market, with a market share of around 60% [1]. Patent Expiration and Entry of Generic Options The European patent for isotretinoin expired in 2003, allowing generic versions of the medication to enter the market. However, the Spain market still holds a significant number of patents, which is one reason for the higher prices observed. Competition from Biosimilars The European Medicines Agency has approved several biosimilars for isotretinoin, including those from Indian companies Sandoz and Zentiva. These biosimilars are expected to gain market share in the coming years [2]. Regulatory Framework The Spain isotretinoin market is governed by the country's regulatory agency, the Spanish Agency for Medicines and Medical Devices (AEMPS). The agency oversees the approval of new medications, including isotretinoin products [3]. Patient Concerns and Side Effects Some patients have expressed concerns regarding the side effects of isotretinoin, including mental health issues and birth defects. It is essential for patients to follow their doctor's advice and adhere to the recommended treatment regimen. References [1] DrugPatentWatch.com. (n.d.). Isotretinoin patents. Retrieved from https://www.drugpatentwatch.com/isotretinoin/Spain/ [2] European Medicines Agency. (2020). Biosimilar medications for isotretinoin. [3] Agencia Española de Medicamentos y Productos Sanitarios (AEMPS). (n.d.). Medicamentos autorizados en España. Retrieved from https://www.aemps.gob.es/ Sources: 1. DrugPatentWatch.com 2. European Medicines Agency 3. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS)
Other Questions About Isotretinoin :